1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Lactate Dehydrogenase

Lactate Dehydrogenase

LDH

Lactate Dehydrogenase (LDH) is an enzyme that catalyzes the conversion of pyruvate, the end product of glycolysis, into lactate (and vice versa) with concomitant interconversion of NADH and NAD+. LDH is comprised of two major subunits, LDH-A and LDH-B, which can assemble into five different isoenzymes (LDH1, LDH2, LDH3, LDH4, and LDH5).

LDH-A is also known as the M subunit as it is predominantly found in skeletal muscle, and LDH-B is also known as the H subunit as it is predominantly found in the heart. LDH-A is a vital metabolic enzyme that is associated with cancer development, invasion, and metastasis. LDH-A is also the key player of the Warburg effect. LDH-A has been reported to correlate with clinicopathologic characteristics and survival outcome of multiple cancers. The inhibition of LDH-A has an anti-proliferative effect on primary breast tumors. LDH-B is a crucial glycolytic enzyme that catalyses conversion of lactate and NAD+ to pyruvate, NADH and H+. LDHB plays an important role in autophagy in cancer cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-180110
    Antiparasitic agent-32
    Inhibitor
    Antiparasitic agent-32 (compound M9), a Piperaquine (HY-B1896) analog, is a potent P. falciparum lactate dehydrogenase (Pf LDH)-targeting antiparasitic agent (Pf3D7 IC50 = 0.40 μM). Antiparasitic agent-32 exhibits significant activity against both Pf asexual and gametocyte stages. Antiparasitic agent-32 exerts antiplasmodial activity through stable and specific noncovalent interactions at the NADH-binding site. Antiparasitic agent-32 can be used for malaria research.
    Antiparasitic agent-32
  • HY-110119
    Galloflavin potassium
    Inhibitor
    Galloflavin potassium is a novel lactate dehydrogenase inhibitor that can be used for the research of cancer. Galloflavin inhibits aerobic glycolysis in PLC/PRF/5 cells and triggers cell death via apoptosis.
    Galloflavin potassium
  • HY-14257
    BMS-191095 hydrochloride
    Inhibitor
    BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects.
    BMS-191095 hydrochloride
  • HY-137162
    Dotarizine
    Inhibitor
    Dotarizine is a novel Piperazine (HY-B0912) derivative and antimigraine agent. Dotarizine exhibits Ca2+ channel blocking properties. Dotarizine decreases the release of lactate dehydrogenase. Dotarizine shows 5-HT receptor blocking effect.
    Dotarizine
Cat. No. Product Name / Synonyms Application Reactivity